Results 41 to 50 of about 181,087 (306)

Chimeric antigen receptor T-cell therapy.

Australian prescriber, 2023
Chimeric antigen receptor T-cell therapies are promising new options for patients with relapsed or refractory diffuse large B-cell lymphoma or acute lymphoblastic leukaemia. They increase complete response rates and the chances of achieving prolonged remission.
Burge, Cale, Vanguru, Vinay, Ho, Phoebe Joy   +2 more
openaire   +2 more sources

Natural killer cell immunotherapy in glioblastoma

Discover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Yoshikazu Kuwahara, Kazuo Tomita, Tomoaki Sato   +5 more
doaj   +1 more source

Chimeric Antigen Receptor beyond CAR-T Cells [PDF]

Cancers, 2021
Chimeric antigen receptors (CAR) are genetically engineered receptors that can recognise specific antigens and subsequently activate downstream signalling. Human T cells engineered to express a CAR, also known as CAR-T cells, can target a specific tumour antigen on the cell surface to mediate a cytotoxic response against the tumour.
Vicky Mengfei Qin, Criselle D’Souza, Paul J. Neeson, Joe Jiang Zhu   +3 more
openaire   +3 more sources

Circumventing antivector immunity: potential use of nonhuman adenoviral vectors [PDF]

, 2014
Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase
Beard C.W., Benkö M., Cauthen A.N., Crawford-Miksza L., Estrella Lopez-Gordo, Gall J., Gall J.G., Gattoni A., Ginsberg H.S., Haviv Y.S., Hofmann C., Iva I. Podgorski, Kajon A.E., Kanerva A., Kass-Eisler A., Kuriyama S., Mastrangeli A., Michou A.I., Nicholas Downes, Ramon Alemany, Rogozhin V.N., Roy S., Seiradake E., Shmarov M.M., Soudais C., Tutykhina I.L., Wang D.Y., Wohlfart C., Ying B., Zakhartchouk A.N., Zeng Q.   +30 more
core   +3 more sources

Drug functional remapping: a new promise for tumor immunotherapy

Frontiers in Oncology
The research and development of new anti-cancer drugs face challenges such as high costs, lengthy development cycles, and limited data on side effects.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Ting Su, Ting Su, Ting Su, Ting Su, Jiexiong Wu, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Minghan Song, Minghan Song, Minghan Song, Canfeng He, Canfeng He, Canfeng He, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Yubin Yang, Yubin Yang, Size Chen, Size Chen, Size Chen, Size Chen   +27 more
doaj   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

BMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama, Yoshitaka Okamoto   +7 more
doaj   +1 more source

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

Cells, 2023
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with
Bryanna Reinhardt, Patrick Lee, Joshua P. Sasine   +2 more
doaj   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core  

EXPRESSION OF A FUNCTIONAL CHIMERIC lg-MHC CLASS II PROTEIN [PDF]

, 1992
composed of the a- and ß-chains of the MHC class I1 I-E molecule fused to antibody V regions derived from anti-human CD4 mAb MT310. Expression vectors were constructed containing the functional, rearranged gene segments coding for the V region domains of
Becker, Andrea, Karlsson, Lars, Peterson, Per A., Rieber, Ernst Peter, Riethmüller, Gert, Weiss, Elisabeth H., Weissenhorn, Winfried, Widera, Georg, Zwirner, Jörg   +8 more
core   +1 more source

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source